Clinical Trial Update: Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for Sapanisertib in patients with stage IV or recurrent lung squamous cell carcinoma shows completed status and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Squamous Cell Carcinoma

Drugs mentioned

• Sapanisertib (sapanisertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Lung Squamous Cell Carcinoma, Stage IV Lung Squamous Cell Carcinoma AJCC v7 | Phase 2 | Status: COMPLETED | Results posted: 2022-04-05